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INTRODUCTION
 Prostate cancer is the most common non cutaneous 
malignancy in the western world.1 Since 1980’s, 
radical prostatectomy is a treatment for clinically 
localized prostate cancer with a life expectancy of > 
10 years and has certainly passed the test of time.1 
While the average incidence of prostate cancer [Age 
–standardized rate (ASR) per 100,000 men per year] 
is reported to be much lower for Asian men i.e. 7.2 
compared to 85.6 in the USA and 59.3 in Europe,2,3 it 
is partly believed to be due to lack of screening, poor 
diagnostic facilities and lack of awareness, especially 
in resource constrained countries. Due to lack of 
national level cancer registry, the epidemiology of 
this disease is not correctly known in Pakistan.4 In 
resource constrained countries like Pakistan, with 
the reasons cited above, a significant proportion of 
patients present late with more advanced disease at 
the time of detection, this makes them unsuitable 
for potentially curative treatment options.
 Locally advanced prostate cancer is the one 
extending beyond the prostate capsule with 
invasion of peri-capsular tissue, apex, bladder 
neck or seminal vesicles but without any lymph 
node involvement or distant metastasis (i.e. T3-T4, 
N0, M0 disease).5 Nearly 20-25% of cases present 
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ABSTRACT
A significant proportion of patients present with locally advanced prostate cancer with inherent higher risk 
of local recurrence and systemic relapse after initial treatment. Recent literature favors combination of 
radiation therapy and extended hormonal therapy for this subset of patients. The effectiveness of Radical 
prostatectomy (RP) alone for locally advanced prostate cancer is controversial and is a focus of debate. 
However, it can decrease the tumor burden and allows the accurate and precise pathological staging with 
the need for subsequent treatment. Comparison of RP and other treatment modalities is difficult and 
incorrect because of inherent selection bias. RP as a part of multi-modality treatment (with neo-adjuvant 
hormonal therapy (HT) and with adjuvant or salvage radiation therapy (RT)/ HT) can provide long term 
overall and cancer specific survival. Surgical treatment (such as transurethral resection (TUR), JJ stenting 
and percutaneous nephrostomy (PCN) placement etc.) can also provide symptomatic improvement and 
palliative care to improve quality of life of patients with advanced prostate cancer.
Sources of data/ study selection: The articles published between years 1998-2014 were searched on 
electronic databases Pubmed, Science direct, Google scholar and Embase and used for preparation of this 
review.
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as locally advanced disease. These patients are at 
increased risk of prostate specific antigen (PSA) 
failure, metastatic progression and cancer specific 
death.5 This definition can be interchangeably used 
with the high risk prostate cancer.
High risk prostate cancer: D’Amico defined 3 
factors which pose high risk to prostate cancer. 
These include clinical stage ≥T2c, serum PSA ≥ 20 
ng/ml or biopsy Gleason score of ≥8.6
Surgical treatment options for locally advanced 
prostate cancer: The surgical treatment options 
include definitive treatment i.e. Radical prostatec-
tomy (RP) with intent to treat and procedures to 
provide palliation and symptomatic relief. 
Predictors of success for Radical prostatectomy 
(RP) in locally advanced prostate cancer: RP is 
considered as a standard of care for organ confined 
disease but traditionally it has been discouraged 
as a definitive treatment option for locally 
advanced prostate cancer because of the concern of 
positive surgical margins, increased risk of lymph 
node metastasis, local and distant relapse and 
consequently death from prostate cancer.7 Hence 
for cT3 disease, the effectiveness of RP in providing 
local tumor control is a focus of debate and is highly 
controversial.8-11
 European association of urology (EAU) guidelines 
now support the role and  recommend RP to be an 
appropriate option for selected patients with small 
low volume T3 tumor, PSA <20 ng/ml, Gleason 
score < 8 and life expectancy of > 10 years.12
 The available tools to pre-operatively define 
patients’ risk of having locally advanced disease are 
imaging studies like Magnetic resonance imaging 
(MRI), pre and post-operative nomograms, PSA 
velocity and it’s doubling time.12 
 Pelvic MRI is the primary imaging study for stag-
ing. The methods employed to improve staging 
accuracy include endo-rectal coil MRI which can 
detect extra prostatic extension > 1 mm with sen-
sitivity of 70% and specificity of 95% and has 100% 
specificity for the involvement of seminal vesicles.13
Advantage of RP: The advantages of surgical 
treatment i.e. RP in locally advanced prostate 
cancer are several. It can decrease the tumor 
burden and allows the accurate and precise 
pathological staging. It therefore, can identify the 
patients who are at high risk of recurrence and can 
be subsequently managed by other combination 
(adjuvant treatment) e.g. external beam radiation 
therapy (EBRT) for margin positive disease or 
seminal vesicle invasion or hormonal therapy (HT) 
for e.g. in case of positive lymph node.7 It has also 
shown longer and durable results in terms of cancer 
specific survival compared to other options.
Technical aspects of RP in locally advanced 
prostate cancer: RP in locally advanced prostate 
cancer requires special expertise and includes 
removal of whole prostate gland en-bloc (b/w 
urethra and bladder) with good apical dissection, 
wide resection of neuro-vascular (NV) bundle and 
complete resection of both seminal vesicles.14 The 
incidence of urinary incontinence and impotence 
are therefore higher in this group as compared to 
early prostate cancer but with increased surgical 
experience, the functional outcome can be improved 
and morbidity can be minimized.14,15 For locally 
advanced prostate cancer, open RP is preferred 
over laparoscopic approach and it should be done 
in high volume centers.16 
 Pelvic lymphadenectomy in cT3 disease is 
indispensible because of higher risk of lymph 
node involvement. The reported incidence of 
lymph node involvement is between 27-41% in 
different series.17,18 Briganti et al. recommended 
extended lymph node dissection to be carried out 
for patients with locally advanced prostate cancer.17 
Heindenreich et al. compared the progression 
free survival (PFS) in patients with standard vs. 
extended lymphadenectomy and found a 35% 
benefit in favor of the later.18
RP as a monotherapy: The data on surgical man-
agement of locally advanced prostate cancer has not 
been investigated or systematically reviewed and 
no large scale randomized controlled trial (RCT) 
is available to show its superiority. Comparison of 
RP with other treatment modalities for locally ad-
vanced prostate cancer is difficult and may not be 
correct because of heterogeneous group of patients 
and inherent selection bias of good prognosis pa-
tients in favor of surgery.16,19 A few studies have 
shown promising results of RP for locally advanced 
≥cT3 disease. The oncological outcome and factors 
involved in prognosis of patients with locally ad-
vanced prostate cancer in different studies are pre-
sented in Table-I.
 In a multi-centre, non randomized 2 staged study 
(EORTC 30001), RP was done in clinical stage T3 
patients with good prognosis factors (Age < 70 
years, PSA ≤ 20 ng/ml, Biopsy Gleason score ≤ 7, 
Performance status 0-1 and Unilateral cT3a disease).7 
The authors concluded that RP with extensive 
resection can be beneficial as a monotherapy for 
T3aN0M0 patients.
 Van poppel et al.20 in their study determined the 
efficacy of RP monotherapy in men with clinically 
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T3 disease. They mainly included patients with PSA 
values <10 ng/ml without involvement of seminal 
vesicles or lymph nodes and showed a 5 year bio-
chemical recurrence free survival to be > 60%.
 Gontero et al. in a single institution study showed 
that RP is technically feasible in any clinical ‘T’ 
extension up to M1a disease with acceptable 
morbidity.21 There were 51 patients in their study 
who had advanced disease compared to 152 patients 
with organ confined disease. This study showed no 
significant difference in terms of surgical morbidity 
except for the blood transfusion, operative time 
and lymphocele formation which were higher 
in advanced stage group. The 7 year overall and 
cancer specific survival rates were 77% and 90% in 
advanced group vs. 88% and 99% in organ confined 
groups respectively.21 They also proposed that a 
possible advantage of surgery will be debulking the 
disease and therefore prevention of complications 
related to local cancer progression.
 Hsu et al. in their study attempted to determine 
the prognostic factors for advanced prostate cancer 
after RP in cT3 patients in terms of Biochemical 
progression free survival (BPFS), Clinical 
progression free survival (CPFS), Cancer specific 
survival (CSS) and Overall survival (OS) after 10 
years. On multivariate analysis, they found that 
surgical tumor grade, margin and lymph node 
status were significant factors in clinical progression 
free survival (CPFS) and cancer specific survival 
(CSS) while surgical tumor grade, node status and 
pre-operative PSA levels were significant factors in 
biochemical progression free survival (BPFS).10
 Xylinas et al. studied the role of RP for cT3 
disease with the aim of disease control and 
showed that surgical experience is the main factor 
responsible to reduce peri-operative complications 
and produce better functional results.22 This meta-
analysis shows that the biochemical progression 
free survival (BPFS) i.e. PSA <0.2ng/ml and 10 & 15 
years survival ranges from 45-62%, 43-51% and 10-
49% respectively.  In fact these results were better 
than some of the series of EBRT alone or EBRT in 
combination of hormonal therapy (HT). The results 
however are not comparable because of lack of 
homogeneity. 
 Recently, a meta-analysis was published 
regarding the role of robot assisted radical 
prostatectomy for managing high risk prostate 
Table-I: Outcome and survival of Radical prostatectomy (RP) for locally advanced (≥cT3) prostate cancer.
Study Setting/ Country Year Patient’s Median Outcome BPFS  CPFS  CSS OS Predictive Prognostic
	 	 	 (N)	 follow	up	 assessed	at	 (%)		 (%)	 (%)	 (%)	 factor	identified
    (Months) (years)
Hsu CY Erasmus Medical 2010 164 100 months (5) 50.4 79.7 93.4 87.1 Tumor grade, margin and
et al.10 Centre,      (10) 43.0 68.7 80.3 67.2 node status in CPFS. 
 Netherlands    (15) 38.3 63.5 66.3 37.4 Grade, Nodal status and 
           Pre-operative PSA in BFPS
Xylinas GAU EST,  2009 100 69 months (5) 45  -- 90  --  Gleason score >7, Pathological 
et al.11 France          stage, Positive surgical margin 
           and lymph node in 
           cancer recurrence
Loeb George Town 2007 288 88 months (7) -- 39 92 91 Pathological stage in
et al.15 University School   (10) -- 35 88 74 biochemical progression
 of Medicine, US
Freedland John Hopkins 2007 58 156 months (5) 62 90 98 --  Lymph node metastasis
et al.9 Hospital, US    (10) 49 80 91 --  in cancer death
     (15) 49 73 84 --
Gontero Italy 2007 51 48 months (7) --  -- 90.2  76.7  -------------------
et al.21
Carver Memorial Sloan 2006 176 76 months (5) 48 86 94 --  Gleason score, Pre-treatment
et al.8 Kattering, US    (10) 44 76 85 --  PSA, Year of surgery in 
           biochemical progression
Ward Mayo Clinic, US 2005 842 123 months (5) 58 85 95 90 Pathological grade,
et al.14     (10) 43 73 90 76 Ploidy and Margin status
     (15) 38 67 79 53
Van den Netherlands 1998 83 52 months (5) 29 59 85 75 Poorly differentiated tumor
Ouden et al.19    (10) -- 31 72 60
BPFS = Biochemical progression free survival,  CPFS =clinical progression free survival,  CSS=Cancer specific survival,  OSS=Overall survival.
Syed Muhammad Nazim et al.
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cancer showing comparable short term results 
to open prostatectomy in terms of its safety and 
functional outcome, however, the long term 
oncological data is still awaited.23
Multi modality treatment: For locally advanced 
prostate cancer, various studies have shown that 
a multi-modality treatment is needed of which 
surgery is only a part. Early adjuvant and late 
salvage radiation (EBRT) or hormonal therapy (HT) 
can be considered in patients with locally advanced 
prostate cancer.12
 A group of urologists at Mayo clinic has long 
been advocating RP as the first line treatment in 
multimodality approach for cT3 disease. Ward 
and colleagues14 in a large retrospective study 
with a follow up of 15 years showed that 78% 
patients with pT3 disease received adjuvant and 
salvage treatment (HT, RT or both) following 
RP.  They categorized RP as an important part of 
multimodality approach for cT3.
Neo-adjuvant and adjuvant treatment to radical 
prostatectomy (RP): Many strategies have been 
devised to prevent the recurrence and improve 
the patient outcome after RP by neo-adjuvant and 
adjuvant therapies.24
Neo-adjuvant hormonal treatment: The aim of neo-
adjuvant hormonal treatment is to shrink the tumor, 
reduce the chance of having a positive margin 
and to reduce both local recurrence and distant 
metastasis in intermediate and high risk patients.25 
However, neo-adjuvant HT is not routinely 
recommended and its role in clinical cT3 prostate 
cancer is controversial. It is also blamed by some 
experts to cause increased operative difficulty.26
 Many studies have shown the impact of short 
term (6 weeks - 4 months) neo-adjuvant HT 
(including complete androgen blockade) before RP. 
A decrease in post operative +ve surgical margins 
is consistently reported along with decrease in 
biochemical recurrence but no effect on global or 
cancer specific survival was observed.24-26
Adjuvant treatment: Adjuvant treatment is defined 
as RT or HT given within 90 days after RP while 
salvage treatment is given post-operatively after 90 
days.14
Post operative adjuvant radiation therapy (RT): 
This approach is proposed in patients with suspicion 
of residual tumor after surgery or with risk of local 
relapse such as positive surgical margins, extra-
capsular extension or seminal vesicle involvement. 
 Two randomized studies compared RP alone with 
RP + adjuvant EBRT for locally advanced prostate 
cancer. In EORTC 22911, Bolla et al. compared RP 
alone (n= 503) versus post-operative 60 Gy adjuvant 
radiation therapy (EBRT) (n= 502) over a six week 
period in patients with positive surgical margins or 
pT3 disease. After a median follow up of 5 years, 
the biochemical progression free survival (BPFS) 
was higher in group who received EBRT (74% vs. 
52.6%, p<0.001) but no improvement in metastasis 
free, cancer specific and overall survival was found. 
The overall tolerability was good with acceptable 
low toxicity.27 They recommended immediate RT 
to those patients who had multifocal +ve surgical 
margins and Gleason score of ≥7. They also 
interpreted that RT can delay the need for HT and 
therefore can postpone its adverse effects.
 Another trial SWOG 8794 compared patients 
with RP alone (n=211) with patients who received 
RP + EBRT (n=214) with pathologically advanced 
prostate cancer (pT3). After a median follow up of 
11.5 years, this trial showed that adjuvant post op 
EBRT significantly reduces the risk of PSA relapse 
(median PSA relapse-free survival 10.3 years 
for combination therapy compared to 3.1 years 
for RP alone, p<0.001), and disease recurrence 
(median disease recurrence- free survival, 13.8 
years for combination therapy vs. 9.9 years for RP 
alone, p=0.001), however, this advantage was not 
translated in terms of difference in overall survival.28 
Adjuvant Hormonal therapy (HT) after RP: The use 
of adjuvant HT after node negative RP was studied 
at Mayo clinic. Siddiqui et al. in a retrospective 
study compared 580 patients who received adjuvant 
ADT with 1160 patients who were observed only. 
Although there was a significant difference in 10 
year biochemical progression free survival (BPFS) 
(95% vs. 90%) and cancer specific survival (98% vs. 
95%), no difference in overall survival (OS) was 
observed.29
 Messing et al. randomized 98 patients with 
node positive disease after RP to either immediate 
androgen deprivation therapy i.e surgical or 
pharmacological castration) (n=47) versus 
observation only (n=51). The median follow up 
duration was 11.9 years. A significant increase in 
overall survival (64% vs. 45%) in favor of ADT and 
also improvement in PSA recurrence free survival 
(53% vs. 14%) disease free survival (60% vs. 25%) 
and prostate cancer specific survival (85% vs. 51%) 
was observed.30
 It is concluded that all patients with advanced 
prostate cancer must be fully counseled and 
informed about the likelihood of multi-model 
approach after RP i.e. EBRT for positive surgical 
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margin, extra capsular extension (ECE) or seminal 
vesicles (SV) invasion and HT in cases of lymph 
node involvement.22
Salvage therapy after RP: Following RP, a PSA 
value >0.2 ng/ml (two consecutive rise) represents 
recurrent cancer.31 Salvage therapy is considered to 
improve the outcome of these patients but at the cost 
of adverse effects. The choice of salvage treatment 
depends upon location of tumor recurrence and 
aggressiveness of disease.31
PSA relapse after RP: Following RP, the salvage 
treatment options are RT or HT (in the form 
of androgen deprivation therapy (ADT), anti-
androgen monotherpy or combined androgen 
blockade (CAB).
 Local recurrences after RP are best treated with 
salvage RT with 64-66 Gy to the pelvis at a rising 
PSA level (preferably < 0.5 ng/ml).12 Salvage RT 
is given when rising PSA is thought to be due to 
local disease recurrence such as late PSA relapse, 
Gleason < 7, slow PSA doubling time (PSADT) and 
positive surgical margins.12
 In cases which demonstrate short PSADT and 
SV invasion, the chances of microscopic metastasis 
and systemic relapse are higher and therefore the 
appropriate option would be to combine RT with 
HT.32
Comparison of combination therapy involving RP 
with non surgical approach: Akakura et al. showed 
in a randomized trial a comparison of RP + ADT 
with EBRT+ ADT and provided the evidence that 
at 10 years, the outcome of former group was 
better than the later with biochemical progression 
free survival (BFS) of 76.2% vs. 71.1%, clinical 
progression free survival (CPFS) of 83.5% vs. 66.1% 
cancer specific survival (CSS) 85.7% vs. 77.1% and 
overall survival (OS) 67.9% vs. 60.9%.33
 Saito et al.34 compared the outcome difference in 
patients with locally advanced prostate cancer who 
were treated with RP  + hormonal treatment (ADT) 
vs. combined RT + ADT vs. ADT alone, and found 
that RT + ADT or RP + ADT offers better overall 
survival than ADT alone.
 In a study, data from Surveillance, Epidemiology 
and End result (SEER) were reviewed, analyzing 
1093 patients with node –ve or node +ve cT4 
prostate cancer. Only 72 patients (6.6%) underwent 
RP with or without adjuvant treatment. The final 
analysis showed increased overall survival (OS) in 
patients with surgical arm compared to those who 
received RT or HT alone and a survival comparable 
to ones who received RT + HT.35
Palliative surgical treatment options in advanced 
prostate cancer: These options aim to provide pal-
liation and symptomatic control to improve quality 
of life in patients with incurable disease.16
 In the setting of radio-resistant prostate cancer, 
salvage radical prostatectomy is the most effective 
secondary curative treatment with good oncological 
outcome and acceptable morbidity. Due to the 
effects of ionizing radiation on tissues with 
consequent fibrosis and obliteration of anatomical 
planes for dissection, salvage RP causes higher risk 
of complications than primary RP.36
 Obstructive uropathy develops in cases of 
aggressive tumors and therefore is associated with 
significant lower survival. Ureteral or bladder 
neck obstruction is either due to local extension 
of prostate cancer or lymph node metastasis with 
consequent azotemia.37 The surgical treatment 
options include placement of supra-pubic (S/P) 
catheter or transurethral resection (TURP) for 
bladder outlet obstruction and percutaneous 
nephrostomy tube (PCN) or Double J (JJ) stent 
placement in cases of upper tract obstruction. 
Salvage cysto-prostatectomy with urinary diversion 
can be used to palliate the debilitating morbidity 
caused by EBRT such as small capacity bladder 
with intractable hematuria and clot retention.
 Surgical castration is a definitive hormonal 
therapy for metastatic prostate cancer patients 
and is more reliable, cost effective and guarantees 
continued androgen deprivation as compared to 
pharmacological castration.16
Transurethral resection of prostate (TUR): Palliative 
channel TUR can be a safe treatment option for 
patients with bladder outlet obstruction to improve 
urinary symptoms as it provides a wide channel 
to void,38 however, TUR alone can adversely affect 
the oncological outcome and can cause significant 
morbidity. These patients have higher incidence 
of distant metastasis, increased recurrence rate 
and lower survival especially for T3-T4 stage and 
moderately to poorly differentiated tumors.39 This 
is because TUR is associated with dissemination 
of tumor cells and breach of lympho vascular 
channels which promotes vascular spread with 
disease progression and consequently a worsened 
prognosis. This peri-operative dissemination of 
tumor cells has been proved by RT-PCR (Reverse 
transcription –polymerase chain reaction) for the 
detection of PSA mRNA.40
 A population data based (SEER) study with over 
29,000 men with prostate cancer had 2742 (9.3%) 
patients who underwent a TUR after diagnosis 
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of cancer. The data supported the hypothesis 
that TUR carried out within a few months after 
needle biopsy based diagnosis of prostate cancer is 
associated with risk of local tumor progression and 
greater all cause mortality. This data also showed 
that subset of patients who underwent TUR had 
higher incidence of JJ stent placement (odd ratio 
1.76), supra pubic cystostomy (odd ratio 1.9) & PCN 
placement (odd ration 2.46), all of which represent 
signs of local disease progression.39
 Another concern is that normal anatomic 
landmarks may be obscured in patients with diffuse 
carcinoma resulting in a rigidly fixed prostatic fossa 
and bladder neck and distortion of trigone with 
consequent damage to these structures.
 Crain et al. showed that palliative TUR can be 
a technically safe procedure for patients with 
locally advanced prostate cancer with low peri-
operative morbidity, minimal blood loss and 
short hospitalization.38 It provided significant 
improvement in symptoms and urinary flow rate 
but compared to TUR done for a benign prostate 
(BPH), had a higher chances of failed trial without 
catheter (TWOC) and re-operation.
CONCLUSION
 RP forms an important part of multimodality 
approach to locally advanced prostate cancer 
and can provide better outcome (combined with 
adjuvant and salvage treatment if needed)  than RT 
or HT  alone or combination of RT and HT. Large 
volume prospective studies are required to confirm 
these findings. Other surgical treatment such as 
TURP, JJ stenting and PCN placement can provide 
palliative care to improve quality of life of patients 
with advanced prostate cancer.
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